Drug intelligence / Profile preview

MTBhsp70

Development stage
Preclinical
Lead developer
VaxCelerate Consortium
Modality
Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration
Intramuscular, Subcutaneous, Intratumoral
01

Overview

MTBhsp70 (Mycobacterium tuberculosis heat shock protein 70) is a 70 kDa recombinant protein derived from *Mycobacterium tuberculosis* that functions as a potent molecular adjuvant and immunomodulator. It is characterized by its ability to stimulate both innate and adaptive immune responses by interacting with antigen-presenting cells (APCs), such as dendritic cells and monocytes, primarily through receptors like Toll-like receptor 4 (TLR4) and CD40. In the context of oncology and infectious diseases, MTBhsp70 is utilized as a carrier or fusion partner to enhance the immunogenicity of target antigens, promoting the secretion of pro-inflammatory cytokines (IL-12, TNF-α) and the activation of cytotoxic T lymphocytes. Conversely, in autoimmune contexts such as rheumatoid arthritis, MTBhsp70 has demonstrated an anti-inflammatory role by inducing the production of interleukin-10 (IL-10) and modulating the cytokine profile of synovial cells. It is currently being investigated in various preclinical and early-stage research settings for indications including cervical cancer, Lassa fever, and inflammatory arthritis.

Other names
Mycobacterium tuberculosis heat shock protein 70Hsp70 (Mycobacterium tuberculosis)70 kDa heat shock protein (Mycobacterium tuberculosis)
02

Targets

CD40 (Cluster of differentiation 40 receptor)TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on MTBhsp70.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MTBhsp70.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call